GLPG

Galapagos NV is a biotechnology company focused on oncology and immunology and inflammation with a modality-agnostic approach, currently advancing clinical-stage programs including GLPG3667, a TYK2 inhibitor in Phase 2 for dermatomyositis and systemic lupus erythematosus, along with cell therapy candidates GLPG5101, a CD19 CAR-T in Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma, and GLPG5301, a BCMA CAR-T in Phase 1 for relapsed/refractory multiple myeloma, though the company announced in January 2026 its decision to wind down cell therapy activities and focus on GLPG3667 and future business development. Following the wind-down completion expected by the end of the third quarter of

Pipeline

Catalyst Calendar